The text starts here.

Access to Medicines

Our Approach

Advocacy

May 7, 2012

2. Eisai's Policy Positions

Eisai has corporate policies on various public policy issues:

  1. Access to medicines (http://www.eisai.com/company/atm/approach/index.html)
  2. Intellectual property (http://www.eisai.com/company/atm/approach/06.html)
  3. Improving access through affordable pricing
    (http://www.eisai.com/company/atm/approach/04-4.html)
  4. Quality of medicines (http://www.eisai.com/company/atm/approach/04-1.html)
  5. Pharmacovigilance (http://www.eisai.com/company/atm/approach/05.html)
  6. Clinical trial registration and result disclosure
    (http://www.eisai.com/company/atm/approach/02-6.html)

Eisai also supports IFPMA policies on global health issues, some of which are listed below:

  1. Neglected tropical diseases
    (http://www.ifpma.org/global-health/neglected-tropical-diseases.html)
  2. Non-communicable diseases
    (http://www.ifpma.org/global-health/non-communicable-diseases.html)
  3. Technology transfer (http://www.ifpma.org/global-health/access/technology-transfer.html)
  4. Biodiversity (http://www.ifpma.org/innovation/biodiversity.html)
  5. Counterfeit medicines (http://www.ifpma.org/global-health/counterfeits.html)

Related Links